MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 12.03.2026
Plus Therapeutics Langfristiger Schuldenstrom 2011-2026 | PSTV
Langfristiger Schuldenstrom Jährlich Plus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56 K | 44 K | 120 K | 110 K | 111 K | 123 K | 147 K | 14.2 M | 13.6 M | 6.63 M | - | 7.36 M | 3.19 M | 9.78 M | 2.49 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 14.2 M | 44 K | 4.14 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
535 K | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
VistaGen Therapeutics
VTGN
|
561 K | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
3.39 M | $ 16.58 | -3.94 % | $ 12.4 B |  Britain |
 |
Zymeworks
ZYME
|
1.31 M | $ 24.18 | -2.07 % | $ 1.25 B | Canada |
 |
AbbVie
ABBV
|
194 M | $ 209.4 | -0.83 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Altimmune
ALT
|
256 K | $ 3.02 | -5.63 % | $ 266 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.21 | -6.2 % | $ 309 M | Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.6 | -2.8 % | $ 16.3 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.29 | -3.6 % | $ 822 M | Canada |